Altered processing of lipid species within skeletal muscle is often observed during obesity, T2DM, and other metabolic diseases with disrupted processing of species including diacylglycerols (DAGs) and ceramides associated with defects in the insulin signaling pathway (Coen & Goodpaster, 2012; Goodpaster & Wolf, 2004). This evidence concerns the gene INS and metabolic disease.